FDA approval summary: belzutifan for von Hippel-Lindau disease–associated tumors
Abstract On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-
class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) …
class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) …
[HTML][HTML] A review of Von Hippel-Lindau syndrome
N Varshney, AA Kebede… - Journal of Kidney …, 2017 - ncbi.nlm.nih.gov
Abstract Von Hippel-Lindau syndrome (VHL) is a familial neoplastic condition seen in
approximately 1 in 36,000 live births. It is caused by germline mutations of the tumor …
approximately 1 in 36,000 live births. It is caused by germline mutations of the tumor …
Von Hippel–Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood
SP Rednam, A Erez, H Druker, KA Janeway… - Clinical Cancer …, 2017 - AACR
Abstract Von Hippel–Lindau disease (vHL) is a hereditary tumor predisposition syndrome
that places affected individuals at risk for multiple tumors, which are predominantly benign …
that places affected individuals at risk for multiple tumors, which are predominantly benign …
[HTML][HTML] von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance
MLM Binderup, M Smerdel, L Borgwadt… - European Journal of …, 2022 - Elsevier
Abstract von Hippel Lindau disease (vHL) is caused by a hereditary predisposition to
multiple neoplasms, especially hemangioblastomas in the retina and CNS, renal cell …
multiple neoplasms, especially hemangioblastomas in the retina and CNS, renal cell …
von Hippel–Lindau disease
P Chittiboina, RR Lonser - Handbook of clinical neurology, 2015 - Elsevier
Abstract von Hippel–Lindau (VHL) disease is an inheritable condition with an incidence of 1
in 36 000 live births. Individuals with VHL develop benign and malignant tumors including …
in 36 000 live births. Individuals with VHL develop benign and malignant tumors including …
Von Hippel-Lindau disease: current challenges and future prospects
S Gläsker, E Vergauwen, CA Koch… - OncoTargets and …, 2020 - Taylor & Francis
Understanding of molecular mechanisms of tumor growth has an increasing impact on the
development of diagnostics and targeted therapy of human neoplasia. In this review, we …
development of diagnostics and targeted therapy of human neoplasia. In this review, we …
Tumors in von Hippel–Lindau syndrome: from head to toe—comprehensive state-of-the-art review
D Ganeshan, CO Menias, PJ Pickhardt… - Radiographics, 2018 - pubs.rsna.org
Von Hippel–Lindau syndrome (VHL) is an autosomal-dominant hereditary tumor disease
that arises owing to germline mutations in the VHL gene, located on the short arm of …
that arises owing to germline mutations in the VHL gene, located on the short arm of …
Survival and causes of death in patients with von Hippel-Lindau disease
MLM Binderup, AM Jensen… - Journal of medical …, 2017 - jmg.bmj.com
Background Historically, the survival of patients with von Hippel-Lindau disease (vHL) has
been poorer than that of the general population. We aimed to determine whether the survival …
been poorer than that of the general population. We aimed to determine whether the survival …
Von Hippel–Lindau disease: a single gene, several hereditary tumors
J Crespigio, LCL Berbel, MA Dias, RF Berbel… - Journal of …, 2018 - Springer
Abstract The Von Hippel–Lindau (VHL) disease is an autosomal dominant disorder
characterized by the predisposition for multiple tumors caused by germline mutations in the …
characterized by the predisposition for multiple tumors caused by germline mutations in the …
von Hippel–Lindau disease: update on pathogenesis and systemic aspects
Purpose: To provide an update summarizing the biologic pathways governing von Hippel–
Lindau (VHL) disease pathogenesis and to provide an overview of systemic manifestations …
Lindau (VHL) disease pathogenesis and to provide an overview of systemic manifestations …